July 2023 FDA Watch
Key approvals announced in June represented important steps forward for the lab testing industry.
Key approvals announced in June represented important steps forward for the lab testing industry.
Though UDT-related enforcement actions predominate, an uncommon vendor-related case was in the mix this month.
Recent cases involve COVID-19 fraud, UDTs, and the latest HIPAA Right of Access settlement.
These three lab testing areas were the main sources of fraud and abuse revealed in the OIG’s latest Semi-Annual Report to Congress.
Congress is renewing its previous efforts to make Medicare reimbursement of pharmacy testing permanent—here’s what that could mean for labs.